Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can Vitamin-Like supplements save sight in glaucoma?

NCT ID NCT05695027

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests whether taking nicotinamide and pyruvate supplements can help protect the eyes of people with open-angle glaucoma. About 250 adults aged 35 to 85 will take either the supplements or a placebo for 20 months, while continuing their standard glaucoma medications. The goal is to see if the supplements slow damage to the optic nerve and preserve vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotinamide and pyruvate (dietary supplements)
What this could lead to
If it works, this could offer a simple, safe supplement to help preserve vision in people with glaucoma.
What could go wrong
This is a mid-stage trial with 250 participants, so results may not apply to everyone. Supplements may not slow vision loss beyond standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Willing and able to provide informed consent for participation in the study. 2. Between 35 and 85 years of age. 3. Only one eligible eye per patient will be enrolled. If both eyes qualify, study eye will be elected based on the following characteristics (in order of most to least important): 1) disc hemorrhage, 2) higher intraocular pressure (IOP), 3) without previous filtering surgery, 4) better visual acuity. If both eyes meet these four criteria equally, then the study eye will be determined by random assignment. 4. Have a confirmed diagnosis of primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma. 5. If there is a prior reliable 24-2, the MD should be better than -20dB. 6. Able to perform reliable visual field testing with 24-2 Swedish Interactive Threshold Algorithm (SITA)-Standard SAP (defined as false positive rates \<15%, false negative rates \<30%) at the most recent office visit. 7. Have best corrected visual acuity better than or equal to 20/40 in the study eye. 8. Have an IOP (treated or untreated) ≥ 14 mmHg and within 24 months of the baseline visit and one instance of historical IOP ≥ 16 mmHg by patient report or chart. Exclusion Criteria 1. Glaucoma or cataract surgery anticipated in the next 18 months. 2. Have a diagnosis of significant cataract or media opacity affecting the visual field test or imaging studies. 3. Have a diagnosis of dementia, Alzheimer's, or other neurological disease. 4. Have an inability to take or intolerance to nicotinamide and/or pyruvate. 5. Have undergone incisional glaucoma surgery (trabeculectomy, glaucoma drainage implant, or Xen Gel Stent) within the last 12 months. Phacoemulsification ± canalicular micro-invasive glaucoma surgery (MIGS) is acceptable if performed ≥ 4 months prior to study entry. 6. Prior complicated cataract surgery (e.g., vitrectomy, etc) 7. Have a functioning trabeculectomy, glaucoma drainage implant, or Xen Gel Stent (defined as being on 0-1 glaucoma medications). If these surgeries have failed and the patient is on ≥ 2 classes of glaucoma medication and meets all other entry criteria, he/she is eligible). 8. Retinal pathology that significantly affects visual acuity (worse than 20/40) or visual field. 9. Refractive disorders and disorders other than glaucoma known to affect the visual field (VF) and macular optical coherence tomography (OCT) imaging (e.g., epiretinal membrane, cystoid macular edema, pathologic myopia, cylinder \> 3 diopters, prior history of pars plana vitrectomy with internal limiting membrane peel). 10. IOP at screening or baseline visit ≥ 25 mmHg. 11. Have a known history of liver disease. 12. Are pregnant or are planning to become pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary open-angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Irving Medical Center - 622 W 168th St

    New York, New York, 10032, United States

  • ColumbiaDoctors Ophthalmology - 880 Third Avenue

    New York, New York, 10022, United States

  • Stanford University Department of Ophthalmology

    Palo Alto, California, 94303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.